211 related articles for article (PubMed ID: 20001623)
21. Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT).
Ansari SH; Shamsi TS; Siddiqui FJ; Irfan M; Perveen K; Farzana T; Panjwani VK; Yousuf A; Mehboob T
J Pediatr Hematol Oncol; 2007 Nov; 29(11):743-6. PubMed ID: 17984691
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathological and radiological study of Egyptian β-thalassemia intermedia and β-thalassemia major patients: relation to complications and response to therapy.
Mokhtar GM; Tantawy AA; Adly AA; Ismail EA
Hemoglobin; 2011; 35(4):382-405. PubMed ID: 21797705
[TBL] [Abstract][Full Text] [Related]
23. Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E-β-thalassemia): a single center study from Eastern India.
Bohara VV; Ray S; Chakrabarti P; Ray SS; Nath UK; Chaudhuri U
Hemoglobin; 2014; 38(1):44-8. PubMed ID: 24144212
[TBL] [Abstract][Full Text] [Related]
24. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
Italia K; Jain D; Gattani S; Jijina F; Nadkarni A; Sawant P; Nair S; Mohanty D; Ghosh K; Colah R
Blood Cells Mol Dis; 2009; 42(1):25-31. PubMed ID: 18954999
[TBL] [Abstract][Full Text] [Related]
25. Report on patients with non transfusion-dependent β-thalassemia major being treated with hydroxyurea attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013.
Kosaryan M; Karami H; Zafari M; Yaghobi N
Hemoglobin; 2014; 38(2):115-8. PubMed ID: 24471558
[TBL] [Abstract][Full Text] [Related]
26. Role of Genomic Biomarkers in Increasing Fetal Hemoglobin Levels Upon Hydroxyurea Therapy and in β-Thalassemia Intermedia: A Validation Cohort Study.
Kolliopoulou A; Siamoglou S; John A; Sgourou A; Kourakli A; Symeonidis A; Vlachaki E; Chalkia P; Theodoridou S; Ali BR; Katsila T; Patrinos GP; Papachatzopoulou A
Hemoglobin; 2019 Jan; 43(1):27-33. PubMed ID: 31039620
[TBL] [Abstract][Full Text] [Related]
27. Healing of leg ulcers with hydroxyurea in thalassaemia intermedia patients with associated endocrine complications.
Gamberini MR; Fortini M; De Sanctis V
Pediatr Endocrinol Rev; 2004 Dec; 2 Suppl 2():319-22. PubMed ID: 16462721
[TBL] [Abstract][Full Text] [Related]
28. Adverse effects of hydroxyurea in beta-thalassemia intermedia patients: 10 years' experience.
Karimi M; Cohan N; Mousavizadeh K; Falahi MJ; Haghpanah S
Pediatr Hematol Oncol; 2010 Apr; 27(3):205-11. PubMed ID: 20367264
[TBL] [Abstract][Full Text] [Related]
29. Hodgkin's disease in a child with sickle cell disease treated with hydroxyurea.
Moschovi M; Psychou F; Menegas D; Tsangaris GT; Tzortzatou-Stathopoulou F; Nicolaidou P
Pediatr Hematol Oncol; 2001 Sep; 18(6):371-6. PubMed ID: 11554231
[TBL] [Abstract][Full Text] [Related]
30. Gγ-Xmn I polymorphism: a significant determinant of β-thalassemia treatment without blood transfusion.
Ansari SH; Shamsi TS; Munzir S; Khan MT; Erum S; Perveen K; Farzana T; Ashraf M; Mehboob T; Moinuddin M
J Pediatr Hematol Oncol; 2013 May; 35(4):e153-6. PubMed ID: 23389500
[TBL] [Abstract][Full Text] [Related]
31. Echocardiographic finding in beta-thalassemia intermedia and major: absence of pulmonary hypertension following hydroxyurea treatment in beta-thalassemia intermedia.
Karimi M; Borzouee M; Mehrabani A; Cohan N
Eur J Haematol; 2009 Mar; 82(3):213-8. PubMed ID: 19077048
[TBL] [Abstract][Full Text] [Related]
32. Hydroxyurea therapy for diverse pediatric populations with sickle cell disease.
Rogers ZR
Semin Hematol; 1997 Jul; 34(3 Suppl 3):42-7. PubMed ID: 9317200
[TBL] [Abstract][Full Text] [Related]
33. The activity of superoxide dismutase in hydroxyurea-treated E beta thalassemia.
Ajanta H; Chakraborty S; Madhusnata D; Bhattacharya DK; Manisha D
J Assoc Physicians India; 2002 Aug; 50():1034-5. PubMed ID: 12421025
[TBL] [Abstract][Full Text] [Related]
34. Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran.
Karimi M; Haghpanah S; Farhadi A; Yavarian M
Int J Hematol; 2012 Jan; 95(1):51-6. PubMed ID: 22180324
[TBL] [Abstract][Full Text] [Related]
35. Fetal haemoglobin augmentation in E/beta(0) thalassaemia: clinical and haematological outcome.
Singer ST; Kuypers FA; Olivieri NF; Weatherall DJ; Mignacca R; Coates TD; Davies S; Sweeters N; Vichinsky EP;
Br J Haematol; 2005 Nov; 131(3):378-88. PubMed ID: 16225658
[TBL] [Abstract][Full Text] [Related]
36. Hydroxyurea responses and fetal hemoglobin induction in beta-thalassemia/HbE patients' peripheral blood erythroid cell culture.
Watanapokasin R; Sanmund D; Winichagoon P; Muta K; Fucharoen S
Ann Hematol; 2006 Mar; 85(3):164-9. PubMed ID: 16389564
[TBL] [Abstract][Full Text] [Related]
37. Clinical response and adverse events in young patients with sickle cell disease treated with hydroxyurea.
Kattamis A; Lagona E; Orfanou I; Psichou F; Ladis V; Kanavakis E; Metaxotou-Mavrommati A; Kattamis C
Pediatr Hematol Oncol; 2004 Jun; 21(4):335-42. PubMed ID: 15205096
[TBL] [Abstract][Full Text] [Related]
38. Hydroxyurea therapy in beta-thalassaemia intermedia: improvement in haematological parameters due to enhanced beta-globin synthesis.
Zeng YT; Huang SZ; Ren ZR; Lu ZH; Zeng FY; Schechter AN; Rodgers GP
Br J Haematol; 1995 Jul; 90(3):557-63. PubMed ID: 7646994
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia.
Ansari SH; Shamsi TS; Ashraf M; Perveen K; Farzana T; Bohray M; Erum S; Mehboob T
J Pediatr Hematol Oncol; 2011 Jul; 33(5):339-43. PubMed ID: 21602718
[TBL] [Abstract][Full Text] [Related]
40. The XmnI and BCL11A single nucleotide polymorphisms may help predict hydroxyurea response in Iranian β-thalassemia patients.
Banan M; Bayat H; Azarkeivan A; Mohammadparast S; Kamali K; Farashi S; Bayat N; Khani MH; Neishabury M; Najmabadi H
Hemoglobin; 2012; 36(4):371-80. PubMed ID: 22686296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]